2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Adverse Events, Biological Processes, Genomics, Hematopoiesis, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Bleeding and Clotting, Thrombocytopenias, Bone Marrow Failure Syndromes, Aplastic Anemia, Hemoglobinopathies, Immunology, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Aggressive Lymphoma, Research, AML, MDS, MPN, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2533 Conditioning de-escalation: Comparable outcomes across conditioning intensities after two-step allogeneic hematopoietic stem cell transplantation

Boula Gattas, MD, Xia Bi, MD2, Joanne Filicko-O'Hara, MD3, Joseph Van Galen, MD, MS4, William O'Hara, PharmD5, John Wagner6, Dolores Grosso7, Neal Flomenberg, MD8, Usama Gergis, MD, MBA9
1 Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
2 Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
3 Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
4 Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
5 Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
6 Metrohealth, Cleveland, Ohio, United States
7 Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
8 Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
9 Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

Background

The two-step allogeneic hematopoietic stem cell transplantation (HSCT) platform separates donor lymphocyte infusion (DLI) from CD34-selected stem cell infusion, enabling administration of a fixed donor T-cell dose while protecting hematopoietic stem cells from post-DLI cyclophosphamide. Patients receive DLI (2 × 10⁸ CD3+ T cells/kg) on day −6, cyclophosphamide (50–60 mg/kg/day) on days −3 and −2 to induce bidirectional donor–recipient immune tolerance, followed by infusion of CD34-selected stem cells 24 hours after the second cyclophosphamide dose. This platform has been successfully implemented using myeloablative (MAC), reduced-intensity (RIC), and non-myeloablative (NMA) conditioning. However, the impact of conditioning intensity on transplant outcomes within this platform remains unknown.

Methods

We retrospectively analyzed 387 consecutive patients who underwent two-step HSCT between 2006 and 2025 on IRB-approved clinical trials. All patients received mobilized peripheral blood stem cell grafts. Patients were grouped according to conditioning intensity: MAC (n=230), RIC (n=135), and NMA (n=22). MAC consisted of 12 Gy total body irradiation (TBI) delivered in six fractions. NMA consisted of fludarabine 30 mg/m² for three days plus 4 Gy TBI in two fractions. Most RIC patients received fludarabine 30 mg/m² for four days, 2 Gy TBI, and either busulfan 3.2 mg/kg for two days or melphalan 50 mg/m² for two days. Overall survival (OS), progression-free survival (PFS), relapse, non-relapse mortality (NRM), and graft-versus-host disease (GVHD) were compared across conditioning groups.

Results

The median age of the cohort was 56 years (MAC, 52; RIC, 60; NMA, 68), and the median HCT-CI was 3 (MAC, 2; RIC, 3; NMA, 4), reflecting the expected selection of older and more medically complex patients for lower-intensity conditioning. Acute myeloid leukemia (42%) and myelodysplastic syndromes (13%) were the most common indications for transplantation. Eighty-one percent of patients underwent haploidentical transplantation, while 19% received matched related donor grafts.

For the entire cohort, 1- and 5-year OS were 67.2% (95% CI, 62.6–72.1%) and 54.1% (95% CI, 49.2–59.5%), respectively. Corresponding PFS rates were 60.9% (95% CI, 56.2–66.0%) and 48.5% (95% CI, 43.7–54.0%). The 5-year cumulative incidences of NRM and relapse were 23.6% and 27.8%, respectively. Grade II–IV acute GVHD occurred in 29% of patients, while moderate-to-severe chronic GVHD occurred in 11%.

Despite significant differences in baseline age and comorbidity, conditioning intensity was not associated with differences in outcomes. Three-year OS was 59.0% for MAC, 53.6% for RIC, and 69.3% for NMA (p=0.41), while 3-year PFS was 52.5%, 45.5%, and 69.3%, respectively (p=0.14). NRM was comparable across all conditioning groups. Although relapse was numerically lowest in the NMA cohort (5% at 3 years), this difference did not reach statistical significance (p=0.17), likely reflecting the limited sample size (n=22).

On multivariable analysis, younger age (p=0.003) and MRD transplantation (p=0.003) were independently associated with improved overall survival. Conditioning intensity was not independently associated with OS, PFS, relapse, or NRM.

Conclusions

Within the two-step HSCT platform, de-escalation of conditioning intensity did not compromise OS, PFS, relapse, or non-relapse mortality despite treatment of substantially older and more medically complex patients. These findings support the concept that the efficacy of the two-step platform is driven predominantly by its controlled cellular immunotherapy rather than by conditioning intensity. Prospective studies are ongoing to validate these findings

Usama Gergis, MD, MBA: BioNTech - Stock (publicly traded); IOVANCE Biotherapeutics, Inc. - Stock (publicly traded); Kite, a Gilead Company - Stock (publicly traded); Moderna, Inc. - Stock (publicly traded); Kyverna Therapeutics, Inc. - Honoraria; Autolus Therapeutics PLC - Honoraria; Kite, a Gilead Company - Honoraria; Bristol-Myers Squibb Company - Honoraria; Kite, a Gilead Company - Consultancy (Includes expert testimony); Autolus Therapeutics PLC - Consultancy (Includes expert testimony); Kyverna Therapeutics, Inc. - Consultancy (Includes expert testimony); Bristol-Myers Squibb Company - Consultancy (Includes expert testimony)